{"title":"Nootropic \u0026 Cognitive Peptides","description":"\u003cp\u003eResearch-grade nootropic and cognitive peptides including Semax, Selank, DSIP, PE-22-28, and SS31. High-purity, lab-tested. For research use only.\u003c\/p\u003e","products":[{"product_id":"semax-5mg","title":"Semax 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/SEMAX_5MG_GLOSS.png?v=1779037253\" alt=\"\"\u003eSemax 5mg is a synthetic heptapeptide compound designed for research and laboratory use. This high-purity formulation delivers 5 milligrams of Semax, a synthetic analogue of the adrenocorticotropic hormone (ACTH) 4–7 fragment, suitable for scientific investigation and experimental applications exploring cognitive function, neuroprotection, and neurotrophic factor modulation. Each vial is manufactured to exacting standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying peptide interactions with central nervous system pathways, BDNF expression, and neural plasticity. Store in a cool, dry place away from direct light. For research purposes only.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Semax (synthetic ACTH 4–7 analogue heptapeptide) Concentration: 5mg per vial Purity: Research-grade Format: Lyophilized powder Storage: Cool, dry environment, 2–8°C (refrigerated) Shelf Life: Refer to batch documentation for expiration details Intended Use: Laboratory and research applications only Quality Standard: Manufactured to pharmaceutical-grade consistency protocols Suitable for qualified researchers, academic institutions, and licensed laboratories conducting neuropeptide, cognitive, and neurotrophic research.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₃₈H₅₄N₁₀O₉ Molecular Weight: 751.84 g\/mol CAS Number: 80714-61-0 Sequence: Met-Glu-His-Phe-Pro-Gly-Pro Sequence Classification: Synthetic heptapeptide analogue of the ACTH 4–7 fragment (Met-Glu-His-Phe) with a Pro-Gly-Pro C-terminal extension for enhanced metabolic stability and CNS bioavailability Mechanism: Studied for its ability to upregulate BDNF and NGF expression in the brain, modulate dopaminergic and serotonergic neurotransmission, and exert neuroprotective effects under ischaemic and oxidative stress conditions Purity Analysis: ≥98% by HPLC This molecular data supports advanced research into neuropeptide pharmacology, cognitive enhancement mechanisms, and neurotrophic factor regulation studies.\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store the sealed vial at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and heat sources. Keep in original packaging to protect from light exposure. Unopened vials maintain stability for the duration specified in batch documentation when stored under these conditions. Storage After Reconstitution: Once reconstituted with bacteriostatic water or sterile saline, store the solution at 2–8°C (refrigerated). Reconstituted solution should be used within the timeframe indicated in your batch documentation. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Keep the vial upright and away from direct light during storage. General Handling: Maintain sterile technique during reconstitution. Do not expose to extreme temperatures or prolonged room temperature conditions after mixing. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eSemax: Design, Synthesis, and Neuroprotective Profile\u003c\/strong\u003e\u003cbr\u003eAshmarin IP, et al. (1997). \u003cem\u003eSemax, an analogue of ACTH 4–10 with a broad spectrum of nootropic and neuroprotective properties.\u003c\/em\u003e Zhurnal Vysshei Nervnoi Deyatelnosti, 47(2), 420–430. PMID: 9181054\u003cbr\u003eFoundational paper by the original developers of Semax characterising its design as a metabolically stable ACTH 4–7 analogue with a Pro-Gly-Pro C-terminal extension, demonstrating its nootropic and neuroprotective activity in rodent models and establishing the pharmacological basis for all subsequent Semax CNS research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSemax and BDNF Upregulation in the Rat Brain\u003c\/strong\u003e\u003cbr\u003eDolotov OV, et al. (2006). \u003cem\u003eSemax, an analogue of ACTH 4–7, regulates expression of BDNF and its receptor TrkB in the basal forebrain of rats.\u003c\/em\u003e Journal of Neurochemistry, 97(Suppl 1), 82–86. \u003ca href=\"https:\/\/doi.org\/10.1111\/j.1471-4159.2006.03658.x\"\u003ehttps:\/\/doi.org\/10.1111\/j.1471-4159.2006.03658.x\u003c\/a\u003e\u003cbr\u003eDemonstrates that Semax significantly upregulates BDNF mRNA and TrkB receptor expression in the rat basal forebrain, establishing its neurotrophic mechanism of action and providing the key molecular reference for researchers studying Semax in neuroplasticity, learning, and memory consolidation models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSemax and Neuroprotection in Ischaemic Stroke Models\u003c\/strong\u003e\u003cbr\u003eGusev EI \u0026amp; Skvortsova VI. (2003). \u003cem\u003eBrain ischemia.\u003c\/em\u003e Moscow: Medicina. (See also: Gusev EI, et al. (1997). \u003cem\u003eNeuroprotective effects of Semax in patients with cerebral ischaemia.\u003c\/em\u003e Zhurnal Nevrologii i Psikhiatrii, 97(6), 40–43.) PMID: 9381350\u003cbr\u003eClinical and preclinical investigation of Semax's neuroprotective effects in cerebral ischaemia, demonstrating reduced infarct volume, improved neurological outcomes, and attenuation of oxidative stress — providing the translational research basis for Semax in ischaemic neuroprotection and stroke biology models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSemax and Dopaminergic Neurotransmission: Monoamine Modulation\u003c\/strong\u003e\u003cbr\u003eLevitskaya NG, et al. (2004). \u003cem\u003eInhibition of the ACTH 4–10 analogue Semax on dopamine catabolism in rat brain.\u003c\/em\u003e Bulletin of Experimental Biology and Medicine, 138(5), 477–479. \u003ca href=\"https:\/\/doi.org\/10.1007\/s10517-005-0032-z\"\u003ehttps:\/\/doi.org\/10.1007\/s10517-005-0032-z\u003c\/a\u003e\u003cbr\u003eDemonstrates that Semax inhibits dopamine catabolism in rat brain regions, modulating monoaminergic neurotransmission and providing mechanistic context for researchers studying Semax's effects on dopaminergic signalling, attention, and motivational neuroscience models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSemax and Gene Expression in the Hippocampus: Transcriptomic Analysis\u003c\/strong\u003e\u003cbr\u003eKolomin T, et al. (2013). \u003cem\u003eThe new generation of drugs: peptides, their advantages and limitations.\u003c\/em\u003e International Journal of Peptides, 2013, 386391. (See also: Shadrina MI, et al. (2010). \u003cem\u003eNeuroprotective and neurorestorative effects of Semax peptide in unilateral bulbectomy model in rats.\u003c\/em\u003e Journal of Molecular Neuroscience, 40(1–2), 185–192.) \u003ca href=\"https:\/\/doi.org\/10.1007\/s12031-009-9248-2\"\u003ehttps:\/\/doi.org\/10.1007\/s12031-009-9248-2\u003c\/a\u003e\u003cbr\u003eTranscriptomic and neuroprotective analysis demonstrating Semax-induced regulation of gene networks associated with neurogenesis, synaptic plasticity, and anti-apoptotic signalling in the hippocampus — providing a broad molecular framework for researchers investigating Semax in neural repair, cognitive biology, and neuropeptide gene regulation studies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248662307159,"sku":"XA5","price":14.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/SEMAX_5MG_GLOSS.png?v=1779037254"},{"product_id":"selank-5mg","title":"Selank 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/SELANK_5MG_GLOSS.png?v=1779037208\" alt=\"\"\u003eSelank 5mg is a synthetic heptapeptide compound designed for research and laboratory use. This high-purity formulation delivers 5 milligrams of Selank, a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin, suitable for scientific investigation and experimental applications exploring cognitive function, mood regulation, and immune response modulation. Each vial is manufactured to exacting standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying peptide interactions with neurotransmitter systems, anxiolytic pathways, and immunological responses. Store in a cool, dry place away from direct light. For research purposes only.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Selank (synthetic tuftsin-derived heptapeptide) Concentration: 5mg per vial Purity: Research-grade Format: Lyophilized powder Storage: Cool, dry environment, 2–8°C (refrigerated) Shelf Life: Refer to batch documentation for expiration details Intended Use: Laboratory and research applications only Quality Standard: Manufactured to pharmaceutical-grade consistency protocols Suitable for qualified researchers, academic institutions, and licensed laboratories conducting cognitive, immunological, and neuropeptide research.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₃₄H₆₁N₁₅O₁₂ Molecular Weight: 821.97 g\/mol CAS Number: 61352-05-6 Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro Sequence Classification: Synthetic linear heptapeptide derived from the C-terminal tetrapeptide sequence of tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension for enhanced stability and CNS penetration Mechanism: Modulates GABA-A receptor activity and influences BDNF expression, serotonin, and dopamine neurotransmitter systems; studied for anxiolytic, nootropic, and immunomodulatory properties without sedative effects Purity Analysis: ≥95% by HPLC This molecular data supports advanced research into neuropeptide pharmacology, anxiety pathway modulation, and immune system regulation studies.\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store the sealed vial at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and heat sources. Keep in original packaging to protect from light exposure. Unopened vials maintain stability for the duration specified in batch documentation when stored under these conditions. Storage After Reconstitution: Once reconstituted with bacteriostatic water or sterile saline, store the solution at 2–8°C (refrigerated). Reconstituted solution should be used within the timeframe indicated in your batch documentation. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Keep the vial upright and away from direct light during storage. General Handling: Maintain sterile technique during reconstitution. Do not expose to extreme temperatures or prolonged room temperature conditions after mixing. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank: Design, Synthesis, and Anxiolytic Profile\u003c\/strong\u003e\u003cbr\u003eSemenova TP, et al. (2010). \u003cem\u003eSelank and short peptides of the tuftsin family in the regulation of adaptive behaviour in rats under conditions of emotional stress.\u003c\/em\u003e Peptides, 31(5), 921–926. \u003ca href=\"https:\/\/doi.org\/10.1016\/j.peptides.2010.02.006\"\u003ehttps:\/\/doi.org\/10.1016\/j.peptides.2010.02.006\u003c\/a\u003e\u003cbr\u003eCharacterises Selank’s anxiolytic and anti-stress activity in rodent models of emotional stress, demonstrating dose-dependent attenuation of anxiety-related behaviour without sedation — establishing the foundational pharmacological profile for Selank research in anxiety pathway modulation and stress neurobiology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and BDNF Expression in the Rat Brain\u003c\/strong\u003e\u003cbr\u003eInozemtseva LS, et al. (2008). \u003cem\u003eIntranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus.\u003c\/em\u003e Doklady Biological Sciences, 421(1), 241–243. \u003ca href=\"https:\/\/doi.org\/10.1134\/S0012496608040066\"\u003ehttps:\/\/doi.org\/10.1134\/S0012496608040066\u003c\/a\u003e\u003cbr\u003eDemonstrates that intranasal Selank administration significantly upregulates BDNF mRNA expression in the rat hippocampus, providing the key neurotrophic mechanism of action for researchers studying Selank in neuroplasticity, memory consolidation, and neuroprotective peptide models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and GABAergic Neurotransmission: Anxiolytic Mechanism\u003c\/strong\u003e\u003cbr\u003eZozulya AA, et al. (2001). \u003cem\u003eThe influence of Selank on anxiety-related behaviour in rats: interaction with the GABAergic system.\u003c\/em\u003e Bulletin of Experimental Biology and Medicine, 131(5), 464–466. \u003ca href=\"https:\/\/doi.org\/10.1023\/A:1017928116025\"\u003ehttps:\/\/doi.org\/10.1023\/A:1017928116025\u003c\/a\u003e\u003cbr\u003eDemonstrates Selank’s modulation of GABA-A receptor activity and its interaction with benzodiazepine binding sites, establishing the GABAergic mechanism underlying its anxiolytic effects without sedative or amnesic side effects — providing mechanistic context for researchers studying peptide-based anxiolytic compounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and Immunomodulatory Activity: Tuftsin-Derived Effects\u003c\/strong\u003e\u003cbr\u003eUchakina ON, et al. (2008). \u003cem\u003eImmunomodulatory effects of Selank in patients with anxiety-asthenic disorders.\u003c\/em\u003e Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 71–75. PMID: 18577961\u003cbr\u003eClinical investigation of Selank’s immunomodulatory effects in patients with anxiety disorders, demonstrating normalisation of cytokine profiles (IL-6, TNF-α) and T-cell activity — providing translational evidence for Selank’s dual neuropeptide and immunoregulatory research applications derived from its tuftsin structural origin.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and Enkephalin Metabolism: Opioid System Interaction\u003c\/strong\u003e\u003cbr\u003eKost NV, et al. (2001). \u003cem\u003eSelank inhibits enkephalin-degrading enzymes in human serum.\u003c\/em\u003e Bulletin of Experimental Biology and Medicine, 131(4), 362–364. \u003ca href=\"https:\/\/doi.org\/10.1023\/A:1017945809338\"\u003ehttps:\/\/doi.org\/10.1023\/A:1017945809338\u003c\/a\u003e\u003cbr\u003eDemonstrates that Selank inhibits enkephalin-degrading enzymes in human serum, prolonging endogenous opioid peptide activity and providing a novel mechanistic pathway for its anxiolytic and mood-modulating effects — expanding the research framework for Selank into endogenous opioid system regulation and neuropeptide stability studies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248662470999,"sku":"SK5","price":14.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/SELANK_5MG_GLOSS.png?v=1779037208"},{"product_id":"dsip-15mg","title":"DSIP 15mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/dsip15mgg.png?v=1779538258\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eDelta Sleep-Inducing Peptide (DSIP) 15mg is a synthetic nonapeptide originally isolated from the brain during sleep research. This higher-concentration formulation is designed for research and laboratory use, providing a larger quantity per vial for extended experimental protocols. DSIP has been the subject of scientific investigation into sleep architecture, circadian rhythm regulation, and neuroendocrine modulation. Each vial is manufactured to exacting purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions conducting sleep physiology, peptide biology, and related neuroscience studies. Store in a cool, dry place away from direct light. For research purposes only.\u003c\/p\u003e\n\u003cp\u003ePeptide Composition: Delta Sleep-Inducing Peptide (DSIP) Molecular Weight: 1,117 Da Purity: ≥98% Form: Lyophilized powder Quantity: 15mg per vial Reconstitution: Sterile water or bacteriostatic saline recommended Stability: Store at 2–8°C or −20°C for extended shelf life Half-life: Approximately 6–8 minutes in circulation Research Applications: Sleep architecture, circadian rhythm modulation, neuroendocrine investigations Intended Use: Laboratory and research applications only\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₄₈H₇₁N₁₃O₁₀ Amino Acid Sequence: Ala-Gly-Glu-Asp-Ala-Ser-Gly-Glu-Asp Peptide Chain Length: 9 amino acids (nonapeptide) Molecular Weight: 1,117 Da CAS Number: 62568-57-4 Chemical Classification: Synthetic nonapeptide Structural Class: Linear peptide Isoelectric Point: pH 3.5–4.2\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution Store lyophilised DSIP powder in its original vial at 2–8°C (refrigerator) or −20°C (freezer) for optimal stability. Keep in a cool, dry environment away from direct light and moisture. Properly sealed vials maintain potency for 12–24 months when stored at recommended temperatures. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Storage After Reconstitution Once reconstituted with sterile water or bacteriostatic saline, store the solution at 2–8°C. Reconstituted DSIP remains stable for 7–14 days under refrigeration. For extended storage beyond two weeks, freeze reconstituted solution at −20°C. Thaw at room temperature before use. Use sterile technique during reconstitution and withdrawal to prevent contamination. Do not store at room temperature for extended periods.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP: Original Isolation and Sleep-Inducing Activity\u003c\/strong\u003e\u003cbr\u003eMonnier M \u0026amp; Hösli L. (1964). \u003cem\u003eDialysis of sleep and waking factors in blood of the rabbit.\u003c\/em\u003e Science, 146(3645), 796–798. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.146.3645.796\"\u003ehttps:\/\/doi.org\/10.1126\/science.146.3645.796\u003c\/a\u003e\u003cbr\u003eThe foundational study reporting the isolation of a sleep-promoting factor from rabbit cerebral venous blood during electrically induced sleep, establishing the biological basis for what was later characterised as DSIP and initiating the field of endogenous sleep peptide research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP Characterisation and Nonapeptide Structure\u003c\/strong\u003e\u003cbr\u003eSchönenberger GA \u0026amp; Monnier M. (1977). \u003cem\u003eCharacterization of a delta-electroencephalogram-sleep-inducing peptide.\u003c\/em\u003e Proceedings of the National Academy of Sciences USA, 74(3), 1282–1286. \u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.74.3.1282\"\u003ehttps:\/\/doi.org\/10.1073\/pnas.74.3.1282\u003c\/a\u003e\u003cbr\u003eReports the full structural characterisation of DSIP as a nonapeptide, demonstrating its ability to induce delta-wave sleep in rabbits and establishing the amino acid sequence that underpins all subsequent synthetic DSIP research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP and Sleep Architecture Modulation\u003c\/strong\u003e\u003cbr\u003eNakagaki K, et al. (1986). \u003cem\u003eInfluence of delta sleep-inducing peptide on sleep in rabbits.\u003c\/em\u003e Sleep, 9(1), 138–145. \u003ca href=\"https:\/\/doi.org\/10.1093\/sleep\/9.1.138\"\u003ehttps:\/\/doi.org\/10.1093\/sleep\/9.1.138\u003c\/a\u003e\u003cbr\u003eExamines the dose-dependent effects of exogenous DSIP on sleep stage distribution and circadian sleep–wake patterns in rabbit models, providing quantitative polysomnographic data relevant to sleep architecture and circadian rhythm research protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP and Hypothalamic Neuroendocrine Activity\u003c\/strong\u003e\u003cbr\u003eIyer KS \u0026amp; McCann SM. (1987). \u003cem\u003eDelta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat.\u003c\/em\u003e Brain Research Bulletin, 19(5), 535–538. \u003ca href=\"https:\/\/doi.org\/10.1016\/0361-9230(87)90075-4\"\u003ehttps:\/\/doi.org\/10.1016\/0361-9230(87)90075-4\u003c\/a\u003e\u003cbr\u003eInvestigates DSIP’s neuroendocrine activity at hypothalamic sites, demonstrating selective LH release stimulation and providing mechanistic context for DSIP’s broader role in hypothalamic–pituitary axis modulation beyond sleep regulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP Stress-Limiting Effects in Animal Models\u003c\/strong\u003e\u003cbr\u003eSudakov SK, et al. (1995). \u003cem\u003eDelta sleep-inducing peptide (DSIP): effect on stress-induced changes in behaviour and functional state of rats.\u003c\/em\u003e Peptides, 16(5), 895–901. \u003ca href=\"https:\/\/doi.org\/10.1016\/0196-9781(95)00053-5\"\u003ehttps:\/\/doi.org\/10.1016\/0196-9781(95)00053-5\u003c\/a\u003e\u003cbr\u003eDemonstrates DSIP’s stress-limiting effects in rat models, showing attenuation of stress-induced behavioural and physiological changes — expanding the research scope of DSIP beyond sleep physiology into neuroendocrine stress response and anxiolytic pathway investigations.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248662864215,"sku":"DS15","price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/dsip15mgg.png?v=1779538258"},{"product_id":"dsip-5mg","title":"DSIP 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/dsip-5mg_231b6300-8c7d-460e-9612-2f0b24a0bfbd.png?v=1779537635\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eDelta Sleep-Inducing Peptide (DSIP) is a synthetic nonapeptide originally isolated from the brain of rabbits during sleep studies. This 5mg formulation is designed for research purposes and represents a key compound in sleep physiology investigations. DSIP has been the subject of scientific interest for its potential role in regulating sleep-wake cycles and circadian rhythms. Researchers have explored its mechanisms in modulating sleep architecture and associated neurological processes. Each unit contains 5mg of high-purity DSIP, suitable for laboratory and clinical research applications. Ideal for scientists and institutions investigating peptide biology, sleep neuroscience, and related fields. For research use only. Store in a cool, dry place away from direct light.\u003c\/p\u003e\n\u003cp\u003eSpecification Active Ingredient: Delta Sleep-Inducing Peptide (DSIP) Quantity per Unit: 5mg Purity: High-purity synthetic formulation Peptide Type: Nonapeptide (9 amino acid chain) Form: Lyophilized powder Intended Use: Research and laboratory applications Storage: Cool, dry environment, protected from direct light Stability: Maintain at 2–8°C for optimal shelf life Solubility: Reconstitute with sterile water or appropriate research-grade solvent Research Focus: Sleep physiology, circadian rhythm modulation, sleep architecture studies\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₅₀H₇₅N₁₃O₁₅ Amino Acid Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu Molecular Weight: 1117.23 g\/mol Structure Classification: Linear nonapeptide Composition: Contains 9 amino acid residues with molecular backbone characteristic of endogenous sleep-regulating peptides Purity Standard: ≥95% by HPLC analysis\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution Store lyophilized DSIP powder in its original vial at 2–8°C (refrigerated conditions). Keep in a cool, dry environment protected from direct light and moisture. Avoid repeated freeze-thaw cycles. When stored properly, the lyophilized powder maintains stability for up to 24 months from the date of manufacture. Storage After Reconstitution Once reconstituted with sterile water or appropriate research-grade solvent, store the solution at 2–8°C. Reconstituted DSIP solution should be used within 2–4 weeks to maintain peptide integrity and prevent degradation. For extended storage beyond this period, consider preparing fresh aliquots or storing at −20°C in smaller portions to minimise handling and exposure. Always use sterile technique during reconstitution and storage to prevent contamination.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP: Original Isolation and Sleep-Inducing Activity\u003c\/strong\u003e\u003cbr\u003eMonnier M \u0026amp; Hösli L. (1964). \u003cem\u003eDialysis of sleep and waking factors in blood of the rabbit.\u003c\/em\u003e Science, 146(3645), 796–798. \u003ca href=\"https:\/\/doi.org\/10.1126\/science.146.3645.796\"\u003ehttps:\/\/doi.org\/10.1126\/science.146.3645.796\u003c\/a\u003e\u003cbr\u003eThe foundational study reporting the isolation of a sleep-promoting factor from rabbit cerebral venous blood during electrically induced sleep, establishing the biological basis for what was later characterised as DSIP and initiating the field of endogenous sleep peptide research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP Characterisation and Nonapeptide Structure\u003c\/strong\u003e\u003cbr\u003eSchönenberger GA \u0026amp; Monnier M. (1977). \u003cem\u003eCharacterization of a delta-electroencephalogram-sleep-inducing peptide.\u003c\/em\u003e Proceedings of the National Academy of Sciences USA, 74(3), 1282–1286. \u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.74.3.1282\"\u003ehttps:\/\/doi.org\/10.1073\/pnas.74.3.1282\u003c\/a\u003e\u003cbr\u003eReports the full structural characterisation of DSIP as a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), demonstrating its ability to induce delta-wave sleep in rabbits and establishing the sequence that underpins all subsequent synthetic DSIP research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP and Sleep Architecture Modulation\u003c\/strong\u003e\u003cbr\u003eIyer KS \u0026amp; McCann SM. (1987). \u003cem\u003eDelta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat.\u003c\/em\u003e Brain Research Bulletin, 19(5), 535–538. \u003ca href=\"https:\/\/doi.org\/10.1016\/0361-9230(87)90075-4\"\u003ehttps:\/\/doi.org\/10.1016\/0361-9230(87)90075-4\u003c\/a\u003e\u003cbr\u003eInvestigates DSIP’s neuroendocrine activity at hypothalamic sites, demonstrating selective LH release stimulation and providing mechanistic context for DSIP’s broader role in hypothalamic–pituitary axis modulation beyond sleep regulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP and Circadian Rhythm Regulation\u003c\/strong\u003e\u003cbr\u003eNakagaki K, et al. (1986). \u003cem\u003eInfluence of delta sleep-inducing peptide on sleep in rabbits.\u003c\/em\u003e Sleep, 9(1), 138–145. \u003ca href=\"https:\/\/doi.org\/10.1093\/sleep\/9.1.138\"\u003ehttps:\/\/doi.org\/10.1093\/sleep\/9.1.138\u003c\/a\u003e\u003cbr\u003eExamines the dose-dependent effects of exogenous DSIP on sleep stage distribution and circadian sleep–wake patterns in rabbit models, providing quantitative polysomnographic data relevant to sleep architecture and circadian rhythm research protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDSIP: Stress-Limiting and Antioxidant Properties in Animal Models\u003c\/strong\u003e\u003cbr\u003eSudakov SK, et al. (1995). \u003cem\u003eDelta sleep-inducing peptide (DSIP): effect on stress-induced changes in behaviour and functional state of rats.\u003c\/em\u003e Peptides, 16(5), 895–901. \u003ca href=\"https:\/\/doi.org\/10.1016\/0196-9781(95)00053-5\"\u003ehttps:\/\/doi.org\/10.1016\/0196-9781(95)00053-5\u003c\/a\u003e\u003cbr\u003eDemonstrates DSIP’s stress-limiting effects in rat models, showing attenuation of stress-induced behavioural and physiological changes — expanding the research scope of DSIP beyond sleep physiology into neuroendocrine stress response and anxiolytic pathway investigations.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248663159127,"sku":"DS5","price":16.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/dsip-5mg_231b6300-8c7d-460e-9612-2f0b24a0bfbd.png?v=1779537643"},{"product_id":"ss31-10mg","title":"SS31 10mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/ss31-10mg_627cd29c-9356-4b11-89e7-afaeea5f0afb.png?v=1779544505\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eMitochondrial support peptide designed for cellular energy optimization. SS31 is a targeted bioactive compound that crosses the blood-brain barrier to support mitochondrial function and ATP production. Each vial contains 10mg of pharmaceutical-grade peptide, ideal for research and performance-focused protocols. Store at 2–8°C. For research purposes only.\u003c\/p\u003e\n\u003cp\u003eActive Ingredient: SS31 (Elamipretide) Quantity: 10mg per vial Purity: Pharmaceutical grade Form: Lyophilized powder Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture Solubility: Reconstitute with sterile water or saline Molecular Weight: 623.7 Da Sequence: D-Arg-2’,6’-dimethyltyrosine-Lys-Phe-NH2 Application: Research and investigational use Sterility: Tested and certified Endotoxin: \u0026lt;5 EU\/vial\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₃₄H₅₂N₁₀O₈ CAS Number: 736992-21-1 IUPAC Name: (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid Exact Mass: 720.39 g\/mol Chemical Class: Tetrapeptide analogue Structural Type: Mitochondrial-targeting peptide Composition: 4 amino acid residues with D-arginine modification Purity Grade: ≥98% (HPLC)\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Temperature: 2–8°C (refrigerated) Container: Original sealed vial Light Protection: Store in dark conditions or original packaging Humidity: Keep in dry environment Duration: Stable for 24 months from manufacture date Handling: Minimise exposure to air and moisture Storage After Reconstitution: Temperature: 2–8°C (refrigerated) Container: Sterile, sealed vial or container Stability: Use within 7 days of reconstitution Preparation: Reconstitute with sterile water or 0.9% saline solution Freeze-Thaw: Avoid repeated freeze-thaw cycles Sterility: Maintain aseptic technique during and after reconstitution Discard: Any unused reconstituted solution after 7 days\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 Design and Mitochondrial Targeting Mechanism\u003c\/strong\u003e\u003cbr\u003eSzeto HH. (2006). \u003cem\u003eCell-permeable, mitochondria-targeted, peptide antioxidants.\u003c\/em\u003e AAPS Journal, 8(2), E277–E283. \u003ca href=\"https:\/\/doi.org\/10.1007\/BF02854898\"\u003ehttps:\/\/doi.org\/10.1007\/BF02854898\u003c\/a\u003e\u003cbr\u003eFoundational paper by the inventor of the SS peptide series, describing the design rationale for SS31 (Elamipretide) as a cell-permeable, mitochondria-targeted antioxidant tetrapeptide. Establishes the cardiolipin-binding mechanism and selective accumulation in the inner mitochondrial membrane.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 and Cardiolipin Interaction: Preserving Mitochondrial Cristae\u003c\/strong\u003e\u003cbr\u003eBirk AV, et al. (2013). \u003cem\u003eThe mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.\u003c\/em\u003e Journal of the American Society of Nephrology, 24(8), 1250–1261. \u003ca href=\"https:\/\/doi.org\/10.1681\/ASN.2012121216\"\u003ehttps:\/\/doi.org\/10.1681\/ASN.2012121216\u003c\/a\u003e\u003cbr\u003eDemonstrates that SS31 binds directly to cardiolipin on the inner mitochondrial membrane, stabilising cristae architecture, restoring electron transport chain efficiency, and improving ATP synthesis in ischaemic renal tissue — a key mechanistic study for mitochondrial bioenergetics research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 in Cardiac Ischaemia-Reperfusion Injury Models\u003c\/strong\u003e\u003cbr\u003eCho J, et al. (2007). \u003cem\u003ePotent mitochondria-targeted peptides reduce myocardial infarction in rats.\u003c\/em\u003e Coronary Artery Disease, 18(3), 215–220. \u003ca href=\"https:\/\/doi.org\/10.1097\/MCA.0b013e3280d609fe\"\u003ehttps:\/\/doi.org\/10.1097\/MCA.0b013e3280d609fe\u003c\/a\u003e\u003cbr\u003eDemonstrates significant reduction in myocardial infarct size following SS31 administration in rat ischaemia-reperfusion models, establishing its cardioprotective profile and supporting research into mitochondrial ROS scavenging during oxidative injury.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSS31 and Skeletal Muscle Mitochondrial Function in Ageing\u003c\/strong\u003e\u003cbr\u003eSiegel MP, et al. (2013). \u003cem\u003eMitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.\u003c\/em\u003e Aging Cell, 12(5), 763–771. \u003ca href=\"https:\/\/doi.org\/10.1111\/acel.12102\"\u003ehttps:\/\/doi.org\/10.1111\/acel.12102\u003c\/a\u003e\u003cbr\u003eShows that acute SS31 treatment rapidly restores mitochondrial membrane potential, increases ATP production, and improves in vivo skeletal muscle contractile function in aged mice — providing key data for research into age-related mitochondrial decline and sarcopenia models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eElamipretide (SS31) Clinical Translation: Heart Failure\u003c\/strong\u003e\u003cbr\u003eGibson CM, et al. (2016). \u003cem\u003eEMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients with ST-segment elevation myocardial infarction.\u003c\/em\u003e European Heart Journal, 37(16), 1296–1303. \u003ca href=\"https:\/\/doi.org\/10.1093\/eurheartj\/ehv597\"\u003ehttps:\/\/doi.org\/10.1093\/eurheartj\/ehv597\u003c\/a\u003e\u003cbr\u003ePhase 2a clinical trial evaluating the safety and tolerability of intravenous elamipretide (SS31\/MTP-131) in STEMI patients, providing translational context for preclinical SS31 research and establishing the compound’s clinical pharmacokinetic and safety profile.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248680132951,"sku":"2S10","price":26.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/ss31-10mg_627cd29c-9356-4b11-89e7-afaeea5f0afb.png?v=1779544505"}],"url":"https:\/\/www.mutantpeptides.com\/collections\/nootropic-cognitive-peptides.oembed","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}